Wedbush Has Optimistic Outlook of ZNTL FY2024 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Analysts at Wedbush lifted their FY2024 earnings per share (EPS) estimates for Zentalis Pharmaceuticals in a research note issued to investors on Wednesday, January 29th. Wedbush analyst R. Driscoll now expects that the company will earn ($2.25) per share for the year, up from their prior forecast of ($2.33). Wedbush has a "Neutral" rating and a $4.00 price objective on the stock. The consensus estimate for Zentalis Pharmaceuticals' current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Zentalis Pharmaceuticals' Q4 2024 earnings at ($0.58) EPS, Q1 2025 earnings at ($0.54) EPS, Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.97) EPS, FY2026 earnings at ($1.63) EPS, FY2027 earnings at ($1.32) EPS and FY2028 earnings at ($0.63) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.36.

ZNTL has been the subject of a number of other research reports. HC Wainwright dropped their price objective on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday, January 29th. Wells Fargo & Company dropped their price target on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating for the company in a research note on Thursday, January 30th. Guggenheim decreased their price objective on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating on the stock in a report on Friday, November 15th. Finally, UBS Group cut their target price on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating for the company in a report on Tuesday, January 28th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Zentalis Pharmaceuticals presently has a consensus rating of "Hold" and a consensus price target of $8.24.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ ZNTL traded up $0.02 during midday trading on Monday, reaching $2.16. The stock had a trading volume of 3,278,452 shares, compared to its average volume of 2,950,098. Zentalis Pharmaceuticals has a 12-month low of $1.61 and a 12-month high of $18.07. The stock has a 50-day moving average of $2.81 and a 200-day moving average of $3.21. The company has a market capitalization of $153.92 million, a price-to-earnings ratio of -0.87 and a beta of 1.82.

Institutional Trading of Zentalis Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. Erste Asset Management GmbH purchased a new position in Zentalis Pharmaceuticals in the 3rd quarter worth about $37,000. Paloma Partners Management Co purchased a new position in shares of Zentalis Pharmaceuticals during the third quarter worth approximately $37,000. Aigen Investment Management LP bought a new stake in shares of Zentalis Pharmaceuticals during the third quarter valued at approximately $41,000. Capstone Investment Advisors LLC purchased a new stake in shares of Zentalis Pharmaceuticals in the third quarter valued at approximately $48,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in Zentalis Pharmaceuticals by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company's stock worth $50,000 after purchasing an additional 5,333 shares in the last quarter.

Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, Director Jan Skvarka acquired 60,000 shares of the company's stock in a transaction that occurred on Friday, January 31st. The stock was bought at an average price of $1.72 per share, for a total transaction of $103,200.00. Following the acquisition, the director now directly owns 149,551 shares in the company, valued at $257,227.72. The trade was a 67.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 3.60% of the stock is owned by insiders.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.